Work

AMPLITUDE: A study of niraparib in combination with abiraterone acetate plus prednisone (AAP) versus AAP for the treatment of patients with deleterious germline or somatic homologous recombination repair (HRR) gene-altered metastatic castration-sensitive prostate cancer (mCSPC).

Year: 2021

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2021.39.6_suppl.tps176

Authors: Dana E. Rathkopf, Kim N. Chi, David Olmos, Heather H. Cheng, Neeraj Agarwal, Julie N Graff, Shahneen Kaur Sandhu, Vinny Hayreh, Angela Lopez-Gitlitz, Peter St. John Francis, Gerhardt Attard

Institutions: Memorial Sloan Kettering Cancer Center, Vancouver Prostate Centre, Spanish National Cancer Research Centre, University of Washington, University of Utah, Huntsman Cancer Institute, Oregon Health & Science University, OHSU Knight Cancer Institute, Peter MacCallum Cancer Centre, Medivation, Inc. (United States), Institute of Cancer Research, Royal Marsden Hospital

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Janssen Research and Development

OpenAlex ID: W3135809902

Cites:

Cited by: 47

Related to: 10